Company
Nine Square Therapeutics
Accelerating the development of better drugs for better targets in a quest to alter the trajectory of neurodegenerative disease.
Also known as Nine Square Therapeutics, Inc.
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Founded
- 2020
- Legal name
- Nine Square Therapeutics, Inc.
- ninesquaretx.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Our scientists combine state-of-the-art tools with the speed of machine learning to study phenotypic changes that distinguish behaviors of dysfunctional from healthy cells. We are boosting autophagy to address genetically validated, but previously undruggable targets with the goal of overcoming the historical challenges of treating severe neurodegenerative diseases.
Funding snapshot
- Total raised
- $4.5MSum of rounds, as of 2026-09-18Source (opens in a new tab)
- Latest round
- Grant, $4.5M2023-09-12
Funding rounds
- Grant
- $4.5M2023-09-12, Company stated
- Round, 2020
- $4.2M2020-06-16, SEC form D sold, 1 investor
Loading relationship preview